Author ORCID Identifier

https://orcid.org/0000-0003-4247-3546

Date Available

4-29-2020

Year of Publication

2020

Degree Name

Master of Science (MS)

Document Type

Master's Thesis

College

Pharmacy

Department/School/Program

Pharmaceutical Sciences

First Advisor

Dr. David Burgess

Abstract

Pseudomonas aeruginosa causes severe healthcare-associated infections. Forty-eight extensively drug-resistant (XDR)-P. aeruginosa isolates were selected from 287 isolates collected for evaluation based on clinical susceptibility data. In vitro activity of commonly utilized antimicrobials (i.e. antipseudomonal beta-lactams, aminoglycosides, fluoroquinolones, and polymyxins) plus ceftolozane-tazobactam, ceftazidime-avibactam, and aztreonam-avibactam against XDR-P. aeruginosa were determined. The mechanism of resistance profile was determined through phenotypic expression analysis. Overall, polymyxin B and colistin were 100% susceptible. Apart from the polymyxins, ceftolozane-tazobactam had the highest susceptibility (94%) followed by ceftazidime-avibactam (90%) and amikacin (83%). Ceftolozane-tazobactam activity was not significantly different from ceftazidime-avibactam (p=0.6831). Only 40% of isolates were susceptible to aztreonam-avibactam. All other agents demonstrated P. aeruginosa at our institution, in vitro analysis proposes superiority of ceftolozane-tazobactam; however, until further in vitro and in vivo validation both agents are reasonable options.

Digital Object Identifier (DOI)

https://doi.org/10.13023/etd.2020.237

Share

COinS